Method of hestosis treatment for pregnant
SUBSTANCE: invention concerns medicine, particularly obstetrics and hestosis treatment for the pregnant. Method involves endovascular laser irradiation of blood for six days. Further, polyphepan is administered internally for eight days in the dosage of 0.5 g per kg of pregnant body weight for 3-4 times per day.
EFFECT: therapeutic effect with reduced treatment duration and medication load on organism of the pregnant due to the selected regimen.
The invention relates to medicine, namely to obstetrics and gynecology, and can be used in the treatment of gestosis.
There is a method of treatment of preeclampsia Sudarikov Mrs x, the Sevastianova O.Y, Pronina T.A. (patent No. 2255776, 2005). This is transcutaneous laser irradiation of the kidneys during pregnancy 30-33 weeks. However, this method does not account for the pathogenesis and possible early (from 20 weeks of gestation) the development of preeclampsia.
There is a method of treatment of preeclampsia Posiseeva L.V., Babakova L.A., Bazhenova M., Panova I.A. (application No. 98104564, published in 2000). The problem is that acupuncture is an invasive and painful procedure. Pregnant women with preeclampsia have increased nervno-mental lability, in this regard, the use of laser puncture in this pathology is not desirable. Also, the method requires the use of sterile or disposable needles.
There is a method of treatment of preeclampsia Khamaganova OR, Evtyugina IV with the application of the enteric sorbent effect Lactofiltrum 2 tablets three times a day an hour before meals for 10-12 days (Syndrome of endogenous intoxication in gestosis, principles of diagnosis and treatment. - Proceedings of the VI Russian forum "Mother and child". - 2004 - s-239).
There is a method of treatment of preeclampsia occurring on the background of nonspecific lung diseases, concomitant use of auto is ultrafioletowego irradiation of blood 2-5 sessions per course and enterosorbent of Boliviana (Starokozheva N.A., Diss. CMN - Voronezh, 1997 - 158 C.).
There is a method of treatment of preeclampsia Assedness and others (patent No. 2.154446 C2, published in 2000) the use of intravascular laser irradiation of blood in 20 minutes a day seven times on the course.
There is a method of treatment of preeclampsia Torchinov A.M., Zahilova YEAR, Austevoll LN. and others with the use of enterosorbent "POLYSORB" 3-4 gr. three times a day an hour before meals for 10-12 days.
The prototype is a method of treatment of preeclampsia mild You a combination of ultraviolet irradiation of blood 2-5 sessions per course and enterosorbent of Politeama one tablespoon three times a day for 10-12 days (the Effects of the introduction of efferent therapy for pregnant women with preeclampsia on the state of the newborn. Efferent therapy. - 2000. - V.6. No. 3. - P.46-51).
The objective of the invention was to develop an effective method of treatment of preeclampsia.
Technical result achieved when using the invention, to improve the results of treatment of preeclampsia, reduced drug load, the improvement of rheological properties of blood, reducing the level of endogenous intoxication, decreased coagulation properties of blood, normalization of processes of lipid peroxidation, stimulation of immunity, the prolongation of pregnancy.
The proposed method of treatment is as follows: hold endovascular laser irradiation of blood (ELOC) on the apparatus ALOKA-1 for 30 minutes once a day from the 1st to the 6th day of treatment, then for eight days enterosorption drug polifan 0.5 g/kg of body weight per day an hour before meals three or four times a day, which is stirred in 50 ml of water. The total course of treatment is 14 days.
The wavelength of the laser radiation of 0.63 μm, the laser power at the output of the fiber is not less than 1 mW. Manufacturer Politeama is JSC "Syntec" St. Petersburg, Russian Federation. Drug polifan selected taking into account the fact that it is readily available, is relatively cheap. It has a high sorption activity and non-specific detoxification effect. In addition to bacterial toxins, heavy metals, drug absorbs too much of some products of metabolism, including bilirubin, cholesterol, urea, metabolites responsible for the development of endogenous intoxication. As a result of ALOK observed favorable changes in the lipid composition of red blood cells, expressed in increased levels of phospholipids. When this normalized aggregation properties, oxygen transport function of erythrocytes. Be improved rheological and reduced coagulation properties of blood, normalization of processes of lipid peroxidation, stimulation of the immune system.
Treated with 60 pregnant women with preeclampsia. Of these 31 women diagnosed with hydrops, 19 - nephrop the party of the first degree, 10 - nephropathy II degree.
The use of ALOK and enterosorption helped to increase the effectiveness of the treatment of preeclampsia by reducing the degree of endogenous intoxication, improve the rheological properties of blood.
Example 1. The pregnant 32 years, first pregnancy, first baby. Nephropathy first degree diagnosed with 34 weeks of gestation. Hospital initiated conventional therapy: anti-hypertensive, infusion, restorative therapy, applied disaggregants. Assigned to endovascular laser irradiation of blood in six days, then enterosorption polyphepanum for eight days. On day 3, blood pressure stabilized, improved General condition, sleep, diuresis. Pregnant 14 days discharged home. Childbirth has occurred through the birth canal during the period of 39 weeks. The post-operative period was uneventful and was discharged home on the 5th day with the child.
Thus, this method of treatment is effective for edema, nephropathy I and II degree. The proposed method made it possible to prolong the pregnancy, to reduce drug load, to reduce the frequency of abdominal delivery.
The simplicity and accessibility of this treatment method can be implemented in all health care institutions.
Treatment of preeclampsia pregnant women, including the irradiation of blood and enterococi what polyphepanum 3-4 times a day, characterized in that conduct intravascular laser irradiation of blood in six days, then enter polifan inside of 0.5 g/kg body weight of pregnant within eight days.
FIELD: medicine, pharmacology.
SUBSTANCE: invention relates to means for prevention or treatment for intrauterine growth retardation or gestational toxicosis, including phenylethanolaminotetralin.
EFFECT: increased means activity.
4 cl, 5 tbl, 2 ex
SUBSTANCE: before and after cervix uteri stiching operating margins are treated with instilagel. Since the second day after operation vagina and vaginal part of cervix uteri are lavaged with epigen twice a day in day and night clinic - 3-4 days. Further treatment with epigen is implemented ambulantly twice a day during 5 more days.
EFFECT: prevention of surgical infection aganst background of progressive pregnancy.
FIELD: organic chemistry, medicine, biochemistry pharmacy.
SUBSTANCE: invention relates to using the known 2-phenyl-substituted imidazotriazinone of the formula (I): (vardenafil) possessing improved properties as compared with other known inhibitors of phosphodiesterase-5 (PDE-5), such as sildenafil and tadalafil. Proposed compound is used for preparing drugs used in treatment of cardiac insufficiency.
EFFECT: valuable medicinal and biochemical properties of compound.
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention relates to substituted diketopiperazines of the general formula (I) or their physiologically acceptable salts wherein R1 means 5-membered cycloalkyl group optionally substituted with one or some hydroxyl groups that is condensed with optionally substituted benzene ring; R2 means (C1-C6)-alkyl; R3 means optionally substituted phenyl, 5- or 6-membered heteroaryl group, or condensed bicyclic ring system comprising 9-10 ring members; R4 means -OH, -O-(C1-C4)-alkyl or -NR5R6. Compounds possess antagonistic effect with respect to oxytocin in oxytocin receptors. Also, invention describes a pharmaceutical composition based on compound of the formula (I), using compounds of the formula (I) for preparing a medicinal agent and methods for synthesis of compounds of the formula (I).
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
16 cl, 227 ex
FIELD: medicine, obstetrics.
SUBSTANCE: at detecting discoordination of uterine contractile activity during the first period of parturition it is necessary to introduce grandaxin at the dosage of 100 mg - 2 tablets once daily till normalization of uterine contractile activity. The innovation provides normalization of parturition process in combination with soft psychostimulating effect in parturient women in case of no side impact upon fetal body.
EFFECT: higher efficiency of therapy.
FIELD: medicine, surgery, surgical gynecology.
SUBSTANCE: one should perorally introduce xymedon at the dosage of 0.5 g to be repeated in 30 min. Then, intravenously one should inject 30 ml provocation-diagnostic curative composition, not more, that consists of aqueous solution of nicotinic acid and polyglucin taken at the following ratio of components, weight%: nicotinic acid 0.05-0.1, polyglucin 0.1-1.8, water - the rest. In case of pain one should diagnose appendicitis. The innovation provides the decrease of incorrect diagnostics in case of acute appendicitis in pregnant women at earlier stages of development along with normalizing action upon gravid uterus.
EFFECT: higher accuracy and efficiency of diagnostics.
1 ex, 1 tbl
SUBSTANCE: method involves intravenously introducing 7.5 mg of Verapamyl dissolved in 100 ml of 0.9% sodium chloride solution as infusion therapy at 2 ml/min rate.
EFFECT: enhanced effectiveness of treatment.
SUBSTANCE: method involves intravenously dropping 5 mg of Ginipral dissolved in 100 ml of 0.9% sodium chloride solution. 5 mg of Verapamyl dissolved in 100 ml of 0.9% sodium chloride solution is intravenously dropped second frequency corresponding to wavelength of 292 nm; photons of the third frequency corresponding to wavelength from 700 to 1400 nm. Photons of the first frequency are produced with one or more continuous radiation laser. Photons of the second and third frequency are produced with one or more pulsating radiation laser. The first, second and third frequency photons are applied to atomic vapor containing several Thallium isotopes. Photons of the first frequency pump Thallium isotope assembly in base state and transfer them to metastable state with energy level of 7793 cm-1 over the first excited state distinguished by energy level of 26477.6 cm-1 relative to zero level of the basic state. The second state photons excite Thallium atoms set in metastable state to intermediate state being the second exited state having energy of 42040.0 cm-1 or 42049.9 cm-1 relative to zero energy of the basic state. Photons of the third frequency ionize the set of atoms belonging to intermediate state. Mentioned isotopic ions are accumulated by applying electric field to the vapor.
EFFECT: enhanced effectiveness in separating thallium isotopes.
10 CL, 7 dwg
SUBSTANCE: method involves determining lymphocyte CD 56+ in peripheral blood before planned pregnancy. The content exceeding norm, lymphocytoimmunotherapy courses are applied with donor lymphocytes. The courses are applied at the fifth-eighth day of fertility cycle until normal lymphocyte CD 56+ values become restored. Pregnancy being proved, lymphocytoimmunotherapy courses are applied with ultrasonic examination results having in view. Choriohypoplasia being available, the courses are applied every 2 weeks. Chorion thickness being in conformity with gestation age, the courses are applied every 3-4 weeks to 12-14 pregnancy weeks.
EFFECT: adequate chorion and placenta development.
SUBSTANCE: invention concerns medicine, laser medicine, and can be applied in treatment of trophic ulcers of venous etiology. Method involves processing of ulcer surface and skin around ulcer by air and gas flow with nitrogen oxide content 2000 ppm or more at 40°C, with 10 second exposition per 1 cm2. Further, 0.1% Radachlorine gel is applied as photo sensitiviser in amount of 0.2 g per 1 cm2 with 60 minutes exposition. Then laser emission of 0.665 mcm wavelength and light energy dosage of 150-200 J/cm2 is applied at 3-5 mm distance from wound surface. Afterwards intravenous blood irradiation is performed over cubital vein by laser emission of 0.632 mcm wavelength and radiation power of 5 mW with 15 minutes exposition. Treatment course comprises 10 daily procedures of air and gas flow processing and intravenous blood irradiation and 5-8 photodynamic therapy procedures performed over 2 day interval.
EFFECT: improved neurotrophic regulation of damaged tissues, antimicrobe effect, reduced frequency of purulent complications, improved blood flow properties, prevented resistance of ulcer microflora to antibiotics and drugs, prevented dysplasia, cicatrical changes and skin malignisation around trophic ulcer.
4 cl, 1 ex
FIELD: medical equipment.
SUBSTANCE: invention concerns medical equipment and can be applied in cancer tissue treatment in various organs of biological objects. Device includes semiconductor laser diode, clock generator, semitransparent mirror, comparator, first, second and third direct current amplifiers, differentiating amplifier, discriminating amplifier, first and second photo receivers, delay line, analog to digital converter, programmed permanent memory, first and second binary code comparators, first and second control systems of secondary power sources, first and second secondary power sources and light panel/indicator. Biological object is positioned in line between semiconductor laser, semitransparent mirror and second photo receiver.
EFFECT: extended range of technical devices for laser cancer therapy.
SUBSTANCE: invention refers to medicine, namely to laser therapy. The first stage of the therapy involves introduction of medicines and intravenous laser blood exposure by installing a needle in one solution transfusion system for quartz fibre of diametre 0.7 mm through which the patient is exposed to helium-neon laser of power 1.2 mW at exposition 90 minutes within seven daily procedures. The second stage includes paravertebral block within herniated disk localisation in projection of herniated disk. Quartz fibre of diametre 0.7 mm is introduced through a puncture needle to the level of surface musculofascial layer. Injection of solution is immediately followed with irradiation with helium-neon laser of power 1.2 mW at exposition 80 minutes within seven daily procedures. Medicines within solution transfusion system are as follows: Trental 5 ml, Actovegin 5 ml, 15% Xantinol Nicotinate 2 ml, vitamin B1 2 ml alternated with vitamin B6 2 ml, 5% vitamin C 3 ml dissolved in physiologic saline 150 ml. Paravertebral block of the first day includes 5% glucocorticoid Diprospan 1 ml combined with 2% Lidocaine. For the following days 2% Lidocaine is used.
EFFECT: method allows terminating inflammatory process, ensuring stable pain management.
SUBSTANCE: therapy of secondary lower limb lymphodema refers to medicine, namely to clinical lymphology. The oatient is exposed to laser light of wavelength 0.6328 mcm combined with intravenous laser irradiation of power 1.2 mW and exposition 90 minutes and intravenous introduction of medicine solutions: Trental, Actovegin, Pheopolyglukine, vitamin B, C complexes, 0.15% xantinol nicotinate. Procedures are daily at seven procedures per course.
EFFECT: therapy provides stable reduction of secondary lower limb lymphodema without therapeutic by-effects, prevents recurrence.
2 cl, 2 ex
SUBSTANCE: invention refers to medicine, to neurology. The therapy involves taking the medicines improving cerebral blood circulations. Pharmacotherapy is combined with exposure to laser light within anconeus and popliteal fold regions. Laser puncture covers the points VB 20 and VB 21 symmetrically downright. Laser light is characterised with wavelength 0.89 mcm, power 3 mW and frequency 600 Hz. Herewith light exposure is 1 minute per each point and 2-3 minutes per elbow and popliteal folds. Therapeutic course is 10 days twice every second month.
EFFECT: method reduces treatment time.
3 ex, 1 tbl
SUBSTANCE: invention relates to medicine, oncology, surgery, radiology, physical therapy and can be used for treating patients with larynx cancer. Area of radiation and surrounding tissues is exposed to infrared laser irradiation. From first day of radioreaction diagnostics, exposure to infrared laser irradiation with constant magnetic field with magnetic induction intensity within 20 mTa, recurrence frequency of pulse laser irradiation of infrared spectrum within 80 Hz, power 0.5-1.0 W on all zone of irradiation is performed with defocused ray for 30-120 seconds. Course includes 3-8 procedures with further application on irradiation zones and intake of a teaspoon of cedar nut oil and before going to bed daily during the whole course of radiation therapy.
EFFECT: method allows to increase efficiency of treatment of early radioreactions and prevent development of later radiation damage reducing severity and frequency of their development.
SUBSTANCE: invention relates to field of medicine, namely to ophthalmology. Laser stroboscopy is carried out during 5 days, 2 times a day with 1 hour interval. First 10 minutes each eye is influenced in turn, then for 5 minutes both eyes are influenced simultaneously. Distance to speckle is 1 m.
EFFECT: recovering binocular functions with elimination of anisoaccomodation, enhancing binocular interaction, increasing visual acuity.
3 cl, 2 ex
SUBSTANCE: invention refers to medicine and aims at epilepsy management. Carotid and vertebral arteries are sequentially exposed to IR laser light, infra-red laser radiation to the right and to the left each for 5 minutes. Frontal, temporal, parietal and occipital lobes are exposed to magnetic field and microwave radiation to the right and to the left each for 3 minutes. And visual analyser is exposed to IR waves within 30 minutes. It is combined with electroencephalographic training with course of treatment 15 procedures.
EFFECT: disclosed method allows for improved mental measurements, relieved remove proneness to convulsive activity, suppressed epileptogenic zones, improved metabolic and energy cerebral processes, normalised cerebral blood flow regulation, recovered cortical neurodynamic disorders.
SUBSTANCE: invention refers to medicine, oncology and to be used for neoadjuvant chemoradiotherapy in the patients suffering from thoracic oesophagus cancer. Said therapy is ensured by introduction of cisplatin and leucovorin, and continuous intravenous infusions of fluorouracil dosed 300 mg/m2. Cisplatin solution is introduced intravenously drop-by-drop and dosed 6 mg/m2 daily once a day within 1 hour. Leucovorin is injected intravenously jet-like and dosed 30 mg/m2. Radiotherapy involves daily fractions 3 Gy to total basic dose 30 Gy. The course dose of fluorouracil is 3600 mg/m2, of cisplatin is 72 mg/m2, of leucovorin 360 mg/m2. Chemotherapy and radiotherapy are to be started the same day.
EFFECT: disclosed method allows for considerably reduced toxicity of treatment to be continuous, treatment of the patients originally of bad performance status, for doubly reduced time of neoadjuvant treatment with maintaining high clinical effectiveness.
SUBSTANCE: invention refers to medicine, urology, physiotherapy and to be used in the patients suffering from chronic pyelonephritis accompanied with chronic prostatitis and chronic cystitis. The method involves taking the mineral water of the Slavjanovsky source dosed 3 - 5 ml per kg of body weight, combined with carbonic mineral baths 35-37°C for 15 minutes 3 times a day, № 8-10, mud "panties" at 40-42°C within 30 minutes to 1.5 hours, prostate massage № 8-10, additionally 50-60 minutes later followed with electropulse therapy combined with exposure to laser magnetic rays. Electropulse therapy involves low-frequency, low-voltage pulse current with a spherical unipolar electrode. Exposure is contact, labile, clockwise and located at skin projection of ascending, transverse and descending large intestine at frequency 30.2 Hz within 8-10 minutes. The course of treatment is 10-12 procedures.
EFFECT: method improves life quality of the patients both in latent phase of inflammatory process, and in mild and moderate active chronic process.
2 ex, 2 tbl
SUBSTANCE: invention concerns medicine and claims therapeutic material and therapeutic media based on it for purulo-necrotic wound treatment, as well as method of obtaining therapeutic material. Material includes activated textile carrier with trypsin, insulin and lysocim immobilised in it.
EFFECT: significant reduction of wound surface cleaning time, accelerated healing.
17 cl, 2 tbl, 9 ex